BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer

Sidse Ehmsen; Rune M Pedersen; Line L Bang; Anders Asmussen; Amalie Kragh; Dorte K Holm; Thomas V Sydenham; Thøger G Jensen; Stefan S Jeppesen; Henrik Frederiksen; Thomas E Andersen; Henrik J Ditzel

doi:10.1016/j.ccell.2023.02.003

BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer

Cancer Cell. 2023 Apr 10;41(4):649-650. doi: 10.1016/j.ccell.2023.02.003. Epub 2023 Feb 9.

Authors

Affiliations

¹ Department of Oncology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Academy of Geriatric Oncology, Odense University Hospital, Odense, Denmark.
² Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Department of Clinical Microbiology, Odense University Hospital, Odense, Denmark.
³ Department of Hematology, Odense University Hospital, Odense, Denmark.
⁴ Department of Oncology, Odense University Hospital, Odense, Denmark.
⁵ Department of Clinical Immunology, Odense University Hospital, Odense, Denmark.
⁶ Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Academy of Geriatric Oncology, Odense University Hospital, Odense, Denmark; Department of Hematology, Odense University Hospital, Odense, Denmark.
⁷ Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Department of Clinical Microbiology, Odense University Hospital, Odense, Denmark. Electronic address: thandersen@health.sdu.dk.
⁸ Department of Oncology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Academy of Geriatric Oncology, Odense University Hospital, Odense, Denmark; OPEN-Open Patient data Exploratory Network, Odense University Hospital, Odense, Denmark; Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark. Electronic address: hditzel@health.sdu.dk.

Abstract

Ehmsen et al. evaluate the neutralizing capacity to current SARS-CoV-2 variants in patients with cancer before and after receiving the BNT162b2 bivalent mRNA vaccine booster. Bivalent vaccine provides some protection against BQ.1.1 but fails to protect against XBB.1 and XBB.1.5 in patients with cancer.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

BNT162 Vaccine
COVID-19* / prevention & control
Humans
Neoplasms* / genetics
Neoplasms* / therapy
RNA, Messenger / genetics
SARS-CoV-2 / genetics

Substances

BNT162 Vaccine
RNA, Messenger

Supplementary concepts

SARS-CoV-2 variants